Breast cancer shot could replace lengthy IV drips
NCT ID NCT04024462
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 trial tested whether a fixed-dose combination of two targeted drugs (pertuzumab and trastuzumab) given as a simple shot under the skin works as well as the standard IV infusion in 200 Chinese patients with HER2-positive early breast cancer. The study measured drug levels in the blood and checked how many patients had no cancer left after treatment. If the shot works, it could save patients time and make treatment more comfortable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pertuzumab and trastuzumab fixed-dose combination for subcutaneous injection (PH FDC SC)
What this could lead to
If successful, this could offer a more convenient, faster subcutaneous injection option instead of lengthy IV infusions for HER2-positive early breast cancer patients.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to other populations or stages. The main focus is on drug levels in the blood, not long-term cure rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Hebei Medical University Fourth Hospital
Shijiazhuang, 050035, China
-
Hubei Cancer Hospital
Wuhan, 430079, China
-
Jiangsu Province Hospital
Nanjing, 210036, China
-
Jilin Cancer Hospital
Changchun, 130012, China
-
Peking University People's Hospital
Beijing, 100044, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, 200025, China
-
Shandong Cancer Hospital
Jinan, 250117, China
-
Sun Yet-sen University Cancer Center
Guangzhou, 510060, China
-
The 900th Hospital of PLA joint service support force
Fuzhou, 110016, China
-
The Affiliated Hospital of Medical College Qingdao University
Qingdao, 266003, China
-
The First Affiliated Hospital of Xian Jiao Tong University
Xi'an, 710061, China
-
The First Hospital of Jilin University
Changchun, 130021, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430023, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China